172 related articles for article (PubMed ID: 36735488)
1. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution of
Iqbal R; Yaqub M; Oprea-Lager DE; Liu Y; Luik AM; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
J Nucl Med; 2022 May; 63(5):694-699. PubMed ID: 34446451
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
4.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
7. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
9.
Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
[TBL] [Abstract][Full Text] [Related]
10. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT.
Bottoni G; Piccardo A; Fiz F; Siri G; Matteucci F; Rocca A; Nanni O; Monti M; Brain E; Alberini JL; Dib B; Sacchetti GM; Saggia C; Rossi V; Harbeck N; Wuerstlein R; Degenhardt T; DeCensi A; Rollandi GA; Gennari A
Eur J Radiol; 2021 Aug; 141():109821. PubMed ID: 34139575
[TBL] [Abstract][Full Text] [Related]
12. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract][Full Text] [Related]
13. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
14. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
[TBL] [Abstract][Full Text] [Related]
16. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature.
Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
[TBL] [Abstract][Full Text] [Related]
17. Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?
Linden HM; Mankoff DA
Clin Cancer Res; 2023 Jun; 29(11):2015-2016. PubMed ID: 36988617
[TBL] [Abstract][Full Text] [Related]
18. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
19. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
20. Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer.
Liu C; Xu X; Yuan H; Zhang Y; Zhang Y; Song S; Yang Z
Front Oncol; 2020; 10():580277. PubMed ID: 33251143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]